(RTTNews) – CureVac N. V. (CVAC) announced Tuesday that it presented a phase 2a trial of its COVID-19 candidate vaccine.
The clinically staged biopharmaceutical company said the first player had been dosed in a phase 2a clinical trial of their COVID-19 candidate vaccine, CvnCoV.
The dose confirmation study, entitled CV-NCOV-002, is underway in Peru and Panama and will recruit a total of 690 participants.
Participants will receive two vaccines at 28-day intervals. Different dose grades will be studied to verify protection and evaluate the reactogenicity of the vaccine in the elderly.
The design of the exam was coordinated and approved by the government of fitness and ethics committees in Peru and Panama, and is based on the initial knowledge of protection and immunogenicity of the ongoing CureVac Phase 1 CV-NCOV-001 exam in adult volunteers in good physical condition in Germany and Belgium.